Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel Group, Phase III Trial to Compare the Efficacy, Safety, and Immunogenicity of TX05 With Herceptin® in Subjects With HER2 Positive Early Breast Cancer

NCT03556358 is registered in ClinicalTrials.gov with Tanvex BioPharma USA, Inc. as lead sponsor.

NCT NCT03556358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03556358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel Group, Phase III Trial to Compare the Efficacy, Safety, and Immunogenicity of TX05 With Herceptin® in Subjects With HER2 Positive Early Breast Cancer
Lead sponsor
Tanvex BioPharma USA, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 28, 2018
Completion date
February 4, 2021
Enrollment
809 (actual)
Sites
146

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms, her2-positive breast cancer, stage ii breast cancer, stage iiia breast cancer